Top Markets
Coin of the day
Gwo Xi Stem Cell Applied Technology Co. , Ltd Gwo Xi Stem Cell Applied Technology Co. , Ltd

Gwo Xi Stem Cell Applied Technology Co. , Ltd

6704
Rank in Stocks #24642
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem... Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
Share Price
$0.60736143
Market Cap
$58.28M
Change (1 day)
-1.04%
Change (1 year)
-21.09%
Country
TW
Trade Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)

Category

Revenue for Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)
Revenue in Aug 2026 TTM: 0
According to Gwo Xi Stem Cell Applied Technology Co. , Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.70B -
AU
- -
CH